Vunakizumab (Anti-CTLA-8 / IL-17a)
Vunakizumab (Anti-CTLA-8 / IL-17a) is a recombinant human IgGκ monoclonal antibody that targets interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis. MW: 146.28.
Supplier | Selleck Chemicals |
---|---|
Product # | A2866 |
Sku # | A2866-1mg*5 |
Pricing | 1mg*5, $970.00 |